Scott Reents

CFO

Equibles does not estimate personal net worth.

Get an email with a short summary when AbbVie Inc. publishes a filing, an earnings call transcript or a press release.

About Scott Reents

Scott Reents is recorded as CFO at AbbVie Inc. (ABBV). Scott Reents has spoken on 10 earnings calls and 3 other investor events across 1 company, most recently for AbbVie Inc. on September 9, 2026. AbbVie Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at AbbVie Inc. includes Robert A. Michael (CEO, Chairman, CFO, COO and Board Member), Richard A. Gonzalez (Chairman), Scott T. Reents (CFO) and 5 others.

Scott Reents on recent calls

“I think we spent a lot of time leading into the Humira loss of exclusivity event, thinking about what the future looked like immediately after, but also beyond that.”

CFO, Wells Fargo 21st Annual Healthcare Conference · September 9, 2026

“This acquisition provides AbbVie with multiple high-value pipeline assets. which further strengthen AbbVie's prospects for long-term growth. Under the terms of the proposed deal, AbbVie has agreed to acquire all outstanding shares of Apogee Therapeutics for $135.11 per share in an all-cash transaction.”

CFO, AbbVie Apogee Acquisition Conference Call · June 22, 2026

“No, look, I think from a trend perspective, If you look at, you know, our guidance for the year, if you look at our first quarter results, very strong first quarter, double growth, you know, SkyRizzy and Renvogue, you know, they're many years into the launch.”

CFO, Goldman Sachs 47th Annual Global Healthcare Conference · June 9, 2026

“Starting with our fourth quarter results, we reported adjusted earnings per share of $2.71, which is $0.08 above our guidance midpoint. These results include a $0.71 unfavorable impact from acquired IPR&D expense.”

CFO, AbbVie Inc. Q4 FY2025 Earnings Call · February 4, 2026